Prospective cohort study to investigate the clinical factors associated with the prognosis of newly diagnosed multiple myeloma in National Hospital Organizatio
Not Applicable
- Conditions
- MGUS, plasmacytoma and multiple myeloma
- Registration Number
- JPRN-UMIN000014270
- Lead Sponsor
- Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
A history of the chemotherapy for multiple myeloma.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival (PFS) according to the initial chemotherapy of patients with symptomatic multiple myeloma.
- Secondary Outcome Measures
Name Time Method Overall survival (OS)and treatment toxicity of patients with symptomatic multiple myeloma. Extension rate from MGUS or SMM to symptomatic myeloma. The process evaluation of the diagnosis and treatment of multiple myeloma.